COVID-19: Strides Pharma to conduct bio-equivalence study on favipiravir in India

By: |
Updated: May 21, 2020 3:13 PM

The company has received approval from the Indian drug authorities for conducting human studies on favipiravir in the country, a Strides Pharma Science spokesperson said in a conference call.

Strides Pharma, COVID-19, COVID-19  deaths, favipiravir in India, COVID-19 patients, Glenmark Pharmaceuticals, BSE, latest news on coronavirus outbreakThe drug is a generic version of Japan-based Toyama Chemical’s Avigan and was initially developed to treat influenza in Japan. (Representational image: Reuters photo)

Drug firm Strides Pharma Science on Thursday said it has received approval from Drug Controller General of India (DCGI) to conduct bio-equivalence study for antiviral drug favipiravir in the country. The drug is a generic version of Japan-based Toyama Chemical’s Avigan and was initially developed to treat influenza in Japan. It has shown positive outcomes in several studies on COVID-19 patients.

The company has received approval from the Indian drug authorities for conducting human studies on favipiravir in the country, a Strides Pharma Science spokesperson said in a conference call.

The approval is for carrying out bio-equivalence study to the innovator product (Avigan), he added. The company in an earlier regulatory filing in April had said that it had developed and commercialised favipiravir tablets, and?the product is currently being exported to GCC (Gulf Cooperation Council) countries to treat patients under their treatment programme for COVID-19.

Also read: Check Coronavirus latest updates here: 

It had said that it would immediately apply to Indian drug authorities to commence necessary studies and make the drug available to Indian patients expeditiously.

Another domestic pharma firm Glenmark Pharmaceuticals had earlier this month said it has initiated Phase 3 clinical trials on favipiravir to check its efficacy on COVID-19 patients in India.

Shares of Strides Pharma Science were trading at Rs 426.75 per scrip on the BSE, up 1.35 per cent from its previous close.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Gilead’s remdesivir gets US FDA approval for hospitalized COVID-19 patients
2Cancer researchers discover new organ in throat: What it is? How it can help in better treatment
3Asymptomatic children have low coronavirus levels compared to those with symptoms, study finds